Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Bispecific Antibodies Market, by Indication
1.4.2 North America Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. North America Bispecific Antibodies Market by Indication
4.1 North America Cancer Market by Country
4.2 North America Inflammatory & Autoimmune Disorder Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Bispecific Antibodies Market by Country
5.1 US Bispecific Antibodies Market
5.1.1 US Bispecific Antibodies Market by Indication
5.2 Canada Bispecific Antibodies Market
5.2.1 Canada Bispecific Antibodies Market by Indication
5.3 Mexico Bispecific Antibodies Market
5.3.1 Mexico Bispecific Antibodies Market by Indication
5.4 Rest of North America Bispecific Antibodies Market
5.4.1 Rest of North America Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
Unique Offerings 